Form 4: Lenz Therapeutics CEO Exercises Stock Options
SEC Form 4 Filing
Evert B. Schimmelpennink, CEO of Lenz Therapeutics, exercises stock options and reports changes in beneficial ownership.
Summary
- On July 22, 2024, Evert B. Schimmelpennink, the President, CEO, and Secretary of Lenz Therapeutics, Inc., executed a transaction involving common stock and stock options.
- Schimmelpennink acquired 45,000 shares of common stock at a price of $1.04 per share through the exercise of stock options.
- Following the transaction, Schimmelpennink directly owns 342,106 derivative securities.
- The shares were issued pursuant to the company's 2020 Equity Incentive Plan, with vesting occurring over time based on continued service.
Sentiment
Score: 5
Explanation: The document is a standard regulatory filing, so the sentiment is neutral. It reflects routine transactions related to executive compensation.
Industry Context
This filing is a routine disclosure related to executive compensation and stock ownership, common in publicly traded companies. It provides transparency to investors regarding the holdings and transactions of company insiders.
Stakeholder Impact
- The transaction provides transparency to shareholders regarding executive stock ownership.
- The vesting schedule incentivizes the CEO to remain with the company.
Key Dates
| Date | Description |
|---|---|
| March 8, 2021 | Vesting Commencement Date for the stock options. |
| July 22, 2024 | Date of transaction: exercise of stock options and acquisition of common stock. |
| July 23, 2024 | Date of signature on the report. |
| March 7, 2031 | Expiration date of the stock options. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.